{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:21:07Z","timestamp":1791865267854,"version":"4.3.4"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1001\/jamaneurol.2020.0299","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T11:31:05Z","timestamp":1584963065000},"page":"764","source":"Crossref","is-referenced-by-count":74,"title":["Huntingtin-Lowering Therapies for Huntington Disease"],"prefix":"10.1001","volume":"77","author":[{"given":"Blair R.","family":"Leavitt","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, BC Children\u2019s Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly B.","family":"Kordasiewicz","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Carlsbad, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Schobel","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"nbs200001r1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease.","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"nbs200001r2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington disease: a clinical review.","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"nbs200001r3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics.","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"nbs200001r4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajhg.2015.12.018","article-title":"The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease.","volume":"98","author":"Keum","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"pt 4","key":"nbs200001r5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/brain\/awg077","article-title":"Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.","volume":"126","author":"Squitieri","year":"2003","journal-title":"Brain"},{"issue":"6","key":"nbs200001r6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes.","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"issue":"10","key":"nbs200001r7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","article-title":"CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.","volume":"78","author":"Lee","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"nbs200001r8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.31887\/DCNS.2016.18.1\/pnopoulos","article-title":"Huntington disease: a single-gene degenerative disorder of the striatum.","volume":"18","author":"Nopoulos","year":"2016","journal-title":"Dialogues Clin Neurosci"},{"issue":"12","key":"nbs200001r9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington\u2019s disease.","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"nbs200001r10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF02257483","article-title":"Structure and expression of the Huntington\u2019s disease gene: evidence against simple inactivation due to an expanded CAG repeat.","volume":"20","author":"Ambrose","year":"1994","journal-title":"Somat Cell Mol Genet"},{"issue":"3","key":"nbs200001r11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/jmedgenet-2015-103568","article-title":"Identification of novel genetic causes of Rett syndrome\u2013like phenotypes.","volume":"53","author":"Lopes","year":"2016","journal-title":"J Med Genet"},{"issue":"12","key":"nbs200001r12","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/ejhg.2016.74","article-title":"A novel neurodevelopmental disorder associated with compound heterozygous variants in the huntingtin gene.","volume":"24","author":"Rodan","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"6109","key":"nbs200001r13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/326194a0","article-title":"Homozygotes for Huntington\u2019s disease.","volume":"326","author":"Wexler","year":"1987","journal-title":"Nature"},{"issue":"20","key":"nbs200001r14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington\u2019s disease mutation. the sensitivity and specificity of measuring CAG repeats.","volume":"330","author":"Kremer","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"nbs200001r15","first-page":"172","article-title":"Homozygosity in Huntington\u2019s disease.","volume":"36","author":"Durr","year":"1999","journal-title":"J Med Genet"},{"issue":"6","key":"nbs200001r16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1046\/j.1399-0004.2003.00155.x","article-title":"Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene.","volume":"64","author":"Squitieri","year":"2003","journal-title":"Clin Genet"},{"issue":"6","key":"nbs200001r17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nn.4014","article-title":"A SNP in the HTT promoter alters NF-?B binding and is a bidirectional genetic modifier of Huntington disease.","volume":"18","author":"Becanovic","year":"2015","journal-title":"Nat Neurosci"},{"issue":"6","key":"nbs200001r18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis.","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"461","key":"nbs200001r19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease.","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6","key":"nbs200001r20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice.","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"issue":"3","key":"nbs200001r21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.v65:3","article-title":"Sustained effects of nonallele-specific huntingtin silencing.","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann Neurol"},{"issue":"5","key":"nbs200001r22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease.","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"5","key":"nbs200001r23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"issue":"2","key":"nbs200001r24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue.","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat Genet"},{"issue":"5222","key":"nbs200001r25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh.","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"issue":"3","key":"nbs200001r26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat Genet"},{"issue":"12","key":"nbs200001r27","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis.","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"nbs200001r28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073902","article-title":"Huntingtin acts non cell\u2013autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse.","volume":"8","author":"Pla","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"nbs200001r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-170235","article-title":"Is huntingtin dispensable in the adult brain?","volume":"6","author":"Liu","year":"2017","journal-title":"J Huntingtons Dis"},{"key":"nbs200001r30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-662-46344-4","article-title":"Neurobiology of Huntington\u2019s disease.","volume":"22","author":"De Souza","year":"2015","journal-title":"Curr Top Behav Neurosci"},{"issue":"24","key":"nbs200001r31","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s disease.","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"nbs200001r34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007765","article-title":"Hypomorphic mutation of the mouse Huntington\u2019s disease gene orthologue.","volume":"15","author":"Murthy","year":"2019","journal-title":"PLoS Genet"},{"issue":"18","key":"nbs200001r35","doi-asserted-by":"crossref","first-page":"e2101","DOI":"10.1212\/WNL.0000000000007147","article-title":"Clinical manifestations of homozygote allele carriers in Huntington disease.","volume":"92","author":"Cubo","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"nbs200001r36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","article-title":"Translation of microRNA-based huntingtin-lowering therapies from preclinical studies to the clinic.","volume":"26","author":"Miniarikova","year":"2018","journal-title":"Mol Ther"},{"issue":"R1","key":"nbs200001r37","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","article-title":"Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia.","volume":"25","author":"Keiser","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"1","key":"nbs200001r38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","article-title":"Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.","volume":"233","author":"Stiles","year":"2012","journal-title":"Exp Neurol"},{"issue":"pt 4","key":"nbs200001r39","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of huntingtin is well tolerated in the adult rhesus striatum.","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"issue":"12","key":"nbs200001r40","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease.","volume":"19","author":"McBride","year":"2011","journal-title":"Mol Ther"},{"issue":"15","key":"nbs200001r41","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.","volume":"105","author":"McBride","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"nbs200001r42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ng1297-404","article-title":"Huntingtin is required for neurogenesis and is not impaired by the Huntington\u2019s disease CAG expansion.","volume":"17","author":"White","year":"1997","journal-title":"Nat Genet"},{"issue":"7","key":"nbs200001r43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006846","article-title":"Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.","volume":"13","author":"Dietrich","year":"2017","journal-title":"PLoS Genet"},{"issue":"19","key":"nbs200001r44","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.1523\/JNEUROSCI.21-19-07608.2001","article-title":"Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice.","volume":"21","author":"Reiner","year":"2001","journal-title":"J Neurosci"},{"issue":"5","key":"nbs200001r45","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington\u2019s disease.","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"issue":"10","key":"nbs200001r46","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1523\/JNEUROSCI.2443-18.2018","article-title":"Loss-of-huntingtin in medial and lateral ganglionic lineages differentially disrupts regional interneuron and projection neuron subtypes and promotes Huntington\u2019s disease-associated behavioral, cellular, and pathological hallmarks.","volume":"39","author":"Mehler","year":"2019","journal-title":"J Neurosci"},{"issue":"10","key":"nbs200001r47","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/hmg\/ddi147","article-title":"Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.","volume":"14","author":"Van Raamsdonk","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"15","key":"nbs200001r48","article-title":"Translational pharmacokinetic\/pharmacodynamic (PK\/PD) modeling strategy to support RG6042 dose selection in Huntington\u2019s disease (HD) (S16.005).","volume":"92","author":"Sanwald Ducray","year":"2019","journal-title":"Neurology"},{"key":"nbs200001r32","unstructured":"A study to evaluate the efficacy and safety of intrathecally administered RO7234292 (RG6042) in patients with manifest Huntington\u2019s disease. ClinicalTrials.gov identifier: NCT03761849. Updated February 6, 2020. Accessed January 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761849"},{"key":"nbs200001r33","unstructured":"A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7234292 (ISIS 443139) in Huntington\u2019s disease patients who participated in prior investigational studies of RO7234292 (ISIS 443139). ClinicalTrials.gov identifier: NCT03342053. Updated November 13, 2019. Accessed January 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03342053"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2763342\/jamaneurology_leavitt_2020_bs_200001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T15:22:20Z","timestamp":1722612140000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2763342"}},"subtitle":["A Review of the Evidence of Potential Benefits and Risks"],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.0299","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}